PD173074 Licensed by Pfizer

Catalog No.S1264

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.

Price Stock Quantity  
USD 98 In stock
USD 70 In stock
USD 120 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PD173074 Chemical Structure

PD173074 Chemical Structure
Molecular Weight: 523.67

Validation & Quality Control

6 customer reviews :

Quality Control & MSDS

Related Compound Libraries

FGFR Inhibitors with Unique Features

  • Pan FGFR Inhibitor

    BGJ398 (NVP-BGJ398) FGFR1/2/3-selective, IC50=0.9 nM/1.4 nM/1 nM.

  • Most Potent FGFR Inhibitor

    AZD4547 FGFR1, IC50=0.2 nM; FGFR2, IC50=2.5 nM; FGFR3, IC50=1.8 nM.

  • FDA-approved FGFR Inhibitor

    Ponatinib (AP24534) Approved by FDA for resistant or intolerant CML and Ph+ ALL.

  • Newest FGFR Inhibitor

    SSR128129E Orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

Product Information

  • Compare FGFR Inhibitors
    Compare FGFR Products
  • Research Area
  • Inhibition Profile
  • PD173074 Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
Targets FGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
c-Src [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)

 View  More

IC50 ~25 nM 100 nM-200 nM 19.8 μM >50 μM
In vitro PD173074 is an ATP-competitive inhibitor of FGFR1 with Ki of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. [1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. [2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. [3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NCI-H1581MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\LOWlEPTB;MD6wNVIzPSEQvF2=MoG0V2FPT0WU
KG-1NF\ERohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXofXFKSzVyPUCuNFUyOjlizszNMVnTRW5ITVJ?
MFM-223MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTBwMkG1O|Yh|ryPNYrvZ5U2W0GQR1XS
EoL-1-cellNVTLbpp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojqTWM2OD1yLkOyPVg1KM7:TR?=MYPTRW5ITVJ?
ECC10NIHEeoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XqUWlEPTB;MD6zN|g6QCEQvF2=NFq3cI9USU6JRWK=
H-EMC-SSNV\iTJVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLDSZJJUUN3ME2wMlM1PzF3IN88US=>NYfib3pKW0GQR1XS
AN3-CAM4rxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXDRnlKSzVyPUCuOFAyOzNizszNMXLTRW5ITVJ?
HuO-3N1M2nUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHmW21KSzVyPUCuOVQ3PTNizszNNFnPfXlUSU6JRWK=
RT-112NIjUSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;STWM2OD1yLkW0O|AyKM7:TR?=M4PaPHNCVkeHUh?=
NEC8M1XsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37NOGlEPTB;MD61OlI5QSEQvF2=M1fFR3NCVkeHUh?=
D-263MGNX74XoRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPnSW9KSzVyPUCuO|EyPTlizszNNWDDNpRwW0GQR1XS
SW962NIDUNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnMSI9KSzVyPUCuO|g6QDhizszNMnTjV2FPT0WU
BV-173MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmT3TWM2OD1yLki0OlI{KM7:TR?=M4LGO3NCVkeHUh?=
MFE-280MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTBwOEW4O|Ih|ryPNYf5dHNFW0GQR1XS
HuH-7NFHFPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTFwMkS0OlQh|ryPM1\qPXNCVkeHUh?=
RS4-11NFe4WVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlP6TWM2OD1zLkOzPFg3KM7:TR?=MkC5V2FPT0WU
DMS-114NVLNdmxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\OeVNKUUN3ME2xMlM3PzN5IN88US=>MkXaV2FPT0WU
MSTO-211HMlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjuV2FbUUN3ME2xMlQ4Ozd6IN88US=>M4TkeHNCVkeHUh?=
DU-145NILocYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnITWM2OD1zLkW4NlE4KM7:TR?=M4j5TnNCVkeHUh?=
A172MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWT4R5BQUUN3ME2xMlcxOzV3IN88US=>MlLFV2FPT0WU
SBC-1NWnJTpQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2S3PWlEPTB;Mj6wPVQh|ryPMXHTRW5ITVJ?
H9NXvXSYZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1qxRmlEPTB;Mj6xOFMxPiEQvF2=M2TxSXNCVkeHUh?=
NCI-SNU-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHuNWluUUN3ME2yMlE5Ozl2IN88US=>NIHsNoJUSU6JRWK=
NCI-H720MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnCdZk3UUN3ME2yMlIyOjh|IN88US=>MUTTRW5ITVJ?
HCC2218NX22fmlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M37H[WlEPTB;Mj6zO|k{QSEQvF2=MnHRV2FPT0WU
G-401M3fxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljSTWM2OD1{LkS3NVg6KM7:TR?=NWTvR5dpW0GQR1XS
MPP-89NFW3WlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIK0[pdKSzVyPUKuOFg{PjRizszNNHHGPWxUSU6JRWK=
697MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3X3eGlEPTB;Mj62OVM{OSEQvF2=MmC4V2FPT0WU
KARPAS-45M1fMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnqPWlJUUN3ME2yMlcxPzR5IN88US=>NF2ze3pUSU6JRWK=
MG-63NIn6dllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTJwOUSyOlIh|ryPMoT6V2FPT0WU
NTERA-S-cl-D1NX\sZoNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LYOmlEPTB;Mz6wN|Q4OiEQvF2=MoTmV2FPT0WU
G-402NXXiWXJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zSUGlEPTB;Mz6xNlczPyEQvF2=MYrTRW5ITVJ?
NKM-1M3HCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHZcZBKSzVyPUOuNVM2PjRizszNNHfTfo9USU6JRWK=
RH-18MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTNwMUm1PVgh|ryPMlGxV2FPT0WU
NCI-H1092NFPYWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHHTYJkUUN3ME2zMlE6PjlizszNNFvkSpBUSU6JRWK=
RPMI-8226NFTrRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfCXWtKSzVyPUOuNlM1PDdizszNNI\Rbm9USU6JRWK=
GAMGMoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4q4T2lEPTB;Mz60OlU4PiEQvF2=NHHBUYJUSU6JRWK=
HHM3;CU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M320d2lEPTB;Mz60O|Y4PiEQvF2=NWLyfZRlW0GQR1XS
RO82-W-1M1jz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PY[WlEPTB;Mz60PVg2PSEQvF2=MV7TRW5ITVJ?
CCRF-CEMNH;ObIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4[3NmlEPTB;Mz61NFQ5QCEQvF2=M3vtWXNCVkeHUh?=
NBsusSRNUm1c5VoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjOTFlKSzVyPUOuOlM6PjlizszNNHLG[GZUSU6JRWK=
CHL-1NUTjWlFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPtPHU3UUN3ME2zMlY2Pzl7IN88US=>MUTTRW5ITVJ?
LK-2M1OzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TCbmlEPTB;Mz62O|E{OyEQvF2=M2PpT3NCVkeHUh?=
Hs-578-TNWPYbpFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLnc3BKSzVyPUOuOlc5PzNizszNNX3YOmRqW0GQR1XS
CTB-1MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXCTWM2OD1|LkiwNFUyKM7:TR?=MkLoV2FPT0WU
ES5M4rrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWC2[Wo2UUN3ME2zMlg{PjN5IN88US=>M3v1PHNCVkeHUh?=
A204M3zOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTaOZJKSzVyPUOuPVIxPzVizszNNFe5e4JUSU6JRWK=
SW780MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml[5TWM2OD1|LkmyNlQ2KM7:TR?=M4XrNXNCVkeHUh?=
EW-3M3TSeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1X3RmlEPTB;Mz65PFkzOyEQvF2=NX\6RlU4W0GQR1XS
A704MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\yWI9KSzVyPUSuNlg4OjNizszNNFH3OpNUSU6JRWK=
LU-139M{n4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fEcGlEPTB;ND6zNVU{PCEQvF2=NV3sWHVWW0GQR1XS
CAL-72MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPpTWM2OD12LkSxO|Q3KM7:TR?=NXXE[JdUW0GQR1XS
D-336MGMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2K1O2lEPTB;ND60OlgyPyEQvF2=NVXhTG8yW0GQR1XS
LAMA-84NGjjW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LhXGlEPTB;ND61N|MyKM7:TR?=MWrTRW5ITVJ?
GI-ME-NNWDt[HNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTRwNUS4NUDPxE1?M1fpVnNCVkeHUh?=
KM-H2M{\j[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTRwNUWyNlIh|ryPNWHueZF7W0GQR1XS
NCI-H209MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGS0RpdKSzVyPUSuOVgzQDNizszNM1P5VnNCVkeHUh?=
IGROV-1MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3yTWM2OD12Lki3NVY5KM7:TR?=NXvJ[oJyW0GQR1XS
L-363NH7VNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVq2OoExUUN3ME20Mlk3PjZ3IN88US=>NHnISJVUSU6JRWK=
SK-MEL-3NGXhO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU[2eZV2UUN3ME21MlI1ODZizszNMlXKV2FPT0WU
HuO9NYe3SnhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPKcXBKSzVyPUWuN|g5PDNizszNMYjTRW5ITVJ?
NOS-1M3PM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrRTWM2OD13LkeyPVI4KM7:TR?=MXPTRW5ITVJ?
NCI-H1770MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13DU2lEPTB;NT65OVA{OiEQvF2=NX3iXFBEW0GQR1XS
SF126MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\JcpNZUUN3ME22MlIyPDB4IN88US=>NI\WOWlUSU6JRWK=
ML-2M{fHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3:x[2lEPTB;Nj6yOFk4PyEQvF2=NIPJbHdUSU6JRWK=
CHP-134MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;mUGlEPTB;Nj6yOVE5OiEQvF2=MYnTRW5ITVJ?
NCI-H1355M1;2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTZwNEG3N|Mh|ryPMWnTRW5ITVJ?
TE-12M3\KUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\kTWM2OD14LkeyOlcyKM7:TR?=MnjqV2FPT0WU
A4-FukM3;KWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnpSHNiUUN3ME22Mlc{OTR{IN88US=>NWDy[mIxW0GQR1XS
MV-4-11Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVf4c5lyUUN3ME22Mlc3PjJ4IN88US=>M{PhfnNCVkeHUh?=
SK-UT-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTZwOUG3PFQh|ryPNFHVV4lUSU6JRWK=
J-RT3-T3-5MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWq1WGZlUUN3ME23MlA4PzZ2IN88US=>NV;VVIwyW0GQR1XS
ME-180NVP3NpNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLzSGdKUUN3ME23MlExPDB2IN88US=>M{DBfHNCVkeHUh?=
SK-MEL-28NH;W[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\D[VlKSzVyPUeuN|c5OTlizszNNYDlPYxzW0GQR1XS
HAL-01MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTdwNEizOFEh|ryPM3LLXHNCVkeHUh?=
ES8MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvkTWM2OD15Lk[5OlI3KM7:TR?=MoDTV2FPT0WU
DBNVq2VGlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3m4[WlEPTB;OD6xNVUxPCEQvF2=M{nxNXNCVkeHUh?=
SK-NEP-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\xSWlEPTB;OD60PFE1QSEQvF2=NX\5ZZFEW0GQR1XS
COR-L88NXLvd3QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{KzOmlEPTB;OD61NFk5OSEQvF2=NWDOcY1zW0GQR1XS
LB1047-RCCNVTxcYwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDyTWM2OD16LkWyNlEzKM7:TR?=NHHrfnlUSU6JRWK=
NCI-H520MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPwTWM2OD16Lk[yNVU4KM7:TR?=NYfmOmdSW0GQR1XS
SW954NX;WfGpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfGcI91UUN3ME24MlY6Pzh4IN88US=>NXjDfpNsW0GQR1XS
TE-6NGPxNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRThwN{WxOFMh|ryPMWTTRW5ITVJ?
D-283MEDM33NPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zQZWlEPTB;OT6wOlU{PCEQvF2=M{i4N3NCVkeHUh?=
DBTRG-05MGMnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTlwMEm2NFch|ryPNUm1NZVwW0GQR1XS
NCI-H446NWS5NFJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHtSopKSzVyPUmuNlk2OjZizszNNXnr[5RXW0GQR1XS
HOSNIHR[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPMTWM2OD17LkO1NVM1KM7:TR?=M{\od3NCVkeHUh?=
ES4MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHhTWM2OD17LkWwOVk2KM7:TR?=NXnPeYdUW0GQR1XS
EW-13M2HvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTlwOEmwOVUh|ryPMWTTRW5ITVJ?
IST-MES1MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\RO5dSUUN3ME25Mlk1PTN2IN88US=>NIi5[45USU6JRWK=
CAS-1M1;XbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTlwOUe2OVkh|ryPM{j3SnNCVkeHUh?=
EM-2MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2C3VmlEPTB;MUCuNVM6OyEQvF2=NUfpdFhmW0GQR1XS
SW948NGLzO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTFyLkG4PFIh|ryPNEL5PJpUSU6JRWK=
OAW-42NW\1e3l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHETWM2OD1zMD61NlY4KM7:TR?=NIC4XmxUSU6JRWK=
BE-13MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvU[I5KSzVyPUGwMlY2PzZizszNM3rGeXNCVkeHUh?=
KU812NXq2[YZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXX4WYI4UUN3ME2xNE44OzlzIN88US=>M{\GcnNCVkeHUh?=
SK-MEL-30NGPvZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTFyLki5NFEh|ryPMnPCV2FPT0WU
A2780NUC3fZdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTFzLkCzNFgh|ryPMnfFV2FPT0WU
TGBC24TKBM{TmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfyTlA5UUN3ME2xNU4xPzN5IN88US=>NH7GUJpUSU6JRWK=
GOTONX\kdo9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTuVlBKSzVyPUGxMlIxQDRizszNNFnRclRUSU6JRWK=
NCI-H526MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTFzLkO4N|ch|ryPNHTiPYZUSU6JRWK=
BHT-101NIfXSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoH1TWM2OD1zMT60OFU3KM7:TR?=NULLWJdJW0GQR1XS
NCI-H1155M1;DSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXoRo9KSzVyPUGxMlQ6PDdizszNMVfTRW5ITVJ?
MCF7NFjsUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PBXGlEPTB;MUGuOlE3PyEQvF2=MoHnV2FPT0WU
MKN45NYDmU3ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHO0c4VKSzVyPUGxMlc6QTNizszNMXTTRW5ITVJ?
MOLT-16M3\wU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPlVnJKSzVyPUGxMlk3QTJizszNMYDTRW5ITVJ?
YH-13NGKwWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTF{LkCzOFYh|ryPMVvTRW5ITVJ?
P12-ICHIKAWANFG0UHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPub3dKSzVyPUGyMlM5PDVizszNNWPocIR6W0GQR1XS
GR-STMoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HaNGlEPTB;MUKuOVI6PSEQvF2=NEL1RVFUSU6JRWK=
CAKI-1M1zsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoP5TWM2OD1zMj63PVEh|ryPNIf5NpRUSU6JRWK=
LXF-289MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPkT2ZKSzVyPUGzMlA5OzVizszNNITBRXVUSU6JRWK=
MHH-PREB-1M3vCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTF|LkK3NFQh|ryPMUTTRW5ITVJ?
EW-16MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fOe2lEPTB;MUOuN|E5PyEQvF2=NEDFbVlUSU6JRWK=
NCI-H82MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHz5WVFKSzVyPUGzMlQyQTVizszNNVL1Z40zW0GQR1XS
MMAC-SFMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PubmlEPTB;MUOuOFU1PyEQvF2=NVX4SmN2W0GQR1XS
COLO-684MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HZZWlEPTB;MUOuOVMyQCEQvF2=MUnTRW5ITVJ?
QIMR-WILM4W3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jRSWlEPTB;MUOuPFExQSEQvF2=MoXpV2FPT0WU
NB69M2X6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7ETWM2OD1zMz65PFY5KM7:TR?=M3T1NXNCVkeHUh?=
NCI-H2291M1vsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXS3eYxuUUN3ME2xOE41PDV|IN88US=>MmO0V2FPT0WU
MKN7NYDxPYVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M132S2lEPTB;MUSuOlY4PiEQvF2=NETWT4RUSU6JRWK=
HDLM-2Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7YTWM2OD1zNT6xNlg3KM7:TR?=M{\heXNCVkeHUh?=
A253MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fZd2lEPTB;MUWuN|g3QSEQvF2=MlvYV2FPT0WU
SK-LU-1NVnxW2V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3T2fmlEPTB;MUWuPVA6PCEQvF2=MoHqV2FPT0WU
MEG-01NHnORWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHVSGdiUUN3ME2xOU46OTB5IN88US=>MW\TRW5ITVJ?
SK-N-DZMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfmTWM2OD1zNT65N|c3KM7:TR?=M2HTRnNCVkeHUh?=
H4Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFX0S49KSzVyPUG2MlA5QCEQvF2=NYDk[IJiW0GQR1XS
LU-65M4e1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTF4LkOzPFQh|ryPNV;Ye3pTW0GQR1XS
NCI-H1048NEPVfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTF4LkWxOlUh|ryPMUfTRW5ITVJ?
LCLC-97TM1NIi0WoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLEc2hKSzVyPUG2MlU5QDlizszNNGDBRWdUSU6JRWK=
CAL-120NULIeYR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTF4Lkm4O|kh|ryPMYrTRW5ITVJ?
LU-134-AM2TuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mkf2TWM2OD1zNz6zN|kyKM7:TR?=NED0eGFUSU6JRWK=
SK-MEL-1NWLZd4ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HkfmlEPTB;MUeuO|EzPyEQvF2=Mk\WV2FPT0WU
NCI-H69NGP1NFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrXTYZKSzVyPUG3Mlk{ODdizszNMn;tV2FPT0WU
MC116M2C4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVj4UGx6UUN3ME2xO{46PzVizszNNUDPN4RVW0GQR1XS
UMC-11NWnk[GFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fDemlEPTB;MUiuNVc5QCEQvF2=MV\TRW5ITVJ?
HCC1395NIi4PVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zCPGlEPTB;MUiuOFMxOSEQvF2=NFnyZ5JUSU6JRWK=
no-10MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;JTWM2OD1zOD62N|g5KM7:TR?=NX;lc3dWW0GQR1XS
NYM3rsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3E[YdKSzVyPUG5MlA5ODlizszNMXrTRW5ITVJ?
OS-RC-2NIXKXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TmSGlEPTB;MUmuNVI2OiEQvF2=Mn2xV2FPT0WU
D-423MGNGPQ[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGf4[GlKSzVyPUG5MlM6PTJizszNM3HlVnNCVkeHUh?=
LC-2-adNIDmSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nZ[WlEPTB;MUmuO|YyOiEQvF2=NHnHbmpUSU6JRWK=
DU-4475MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTF7Lki4OVIh|ryPNFPh[mVUSU6JRWK=
YKG-1M1\KNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojZTWM2OD1zOT65OlIh|ryPMkHOV2FPT0WU
HCC1569MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnO1TWM2OD1{MD6yOlI1KM7:TR?=NYjuUHpiW0GQR1XS
TYK-nuNVP5b3dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mle3TWM2OD1{MD6yPFQ4KM7:TR?=NIfRPHdUSU6JRWK=
DELNHTRbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHvTWM2OD1{MD65PFA5KM7:TR?=MVrTRW5ITVJ?
MHH-ES-1MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnVTWM2OD1{MT6zOVk4KM7:TR?=Mn;wV2FPT0WU
KARPAS-299MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2WyfGlEPTB;MkGuOVI6KM7:TR?=Mnv0V2FPT0WU
CTV-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XtbmlEPTB;MkGuOlE4OiEQvF2=NInySlNUSU6JRWK=
NCI-H2452MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rrdmlEPTB;MkKuOlY4PyEQvF2=M2rnZXNCVkeHUh?=
D-566MGNVK3VotsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHqcFZYUUN3ME2yNk44PjBzIN88US=>MljGV2FPT0WU
EFO-27Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTJ|LkC2OVEh|ryPMUTTRW5ITVJ?
NCI-H596MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HiN2lEPTB;MkOuPFUzPyEQvF2=NInkVGVUSU6JRWK=
KS-1NF\ycG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;ETWM2OD1{ND6yO|U6KM7:TR?=M{GzeHNCVkeHUh?=
8305CNIXs[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLxXVZPUUN3ME2yOE41ODR3IN88US=>M{W1R3NCVkeHUh?=
A427NVfNbW9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTJ3LkCzNlMh|ryPNYO1TI16W0GQR1XS
COLO-800MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PtZmlEPTB;MkWuNVA3OSEQvF2=MmPLV2FPT0WU
SJRH30MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jaOGlEPTB;MkWuN|kxQCEQvF2=M4TzSnNCVkeHUh?=
MEL-HOM3viemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnWRZJKSzVyPUK1MlQ{OTlizszNMUXTRW5ITVJ?
FTC-133MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfRcVhrUUN3ME2yOU45OTh4IN88US=>M4riTHNCVkeHUh?=
SF295NEfC[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTJ4LkK5OkDPxE1?M3HLT3NCVkeHUh?=
SW1710MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPZTWM2OD1{Nj60NVI{KM7:TR?=M1r5[3NCVkeHUh?=
EFM-19M2rpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV:1WoNDUUN3ME2yOk45OTR3IN88US=>M3HRbHNCVkeHUh?=
NB10NX;KOnRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTJ6LkKyPVch|ryPNXvrZml{W0GQR1XS
TK10M4rYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkH1TWM2OD1{OD6yN|k6KM7:TR?=NHTQc3BUSU6JRWK=
D-502MGM1\EU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUH1UYpiUUN3ME2yPE41KM7:TR?=MUPTRW5ITVJ?
EW-18NUPKT|hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXG[YlqUUN3ME2yPE41Ozh4IN88US=>NF\KUVNUSU6JRWK=
VMRC-RCZNVr2XmN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XybmlEPTB;MkiuPVQyKM7:TR?=NYHiTGR5W0GQR1XS
Ca9-22NELk[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFv3VFlKSzVyPUK5MlQ2PTdizszNNUfRT4RCW0GQR1XS
KYSE-70MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTMUVZmUUN3ME2yPU42Pzh4IN88US=>MnvyV2FPT0WU
A101DNUKwRW1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHVOYtKSzVyPUK5MlY1PzJizszNNHSwXpJUSU6JRWK=
WM-115NE\uUnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm[3TWM2OD1{OT63OlA4KM7:TR?=MkHTV2FPT0WU
HCC2157NIjvWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLHR4hoUUN3ME2yPU45QDB5IN88US=>NF21VoxUSU6JRWK=
TE-9M1jpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3VTWM2OD1{OT64PFY2KM7:TR?=M{nvPHNCVkeHUh?=
K-562MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTNyLkC5N|Mh|ryPNGPBUVBUSU6JRWK=
SN12CMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTNyLkG0NlYh|ryPMUDTRW5ITVJ?
ESS-1NWWwZW5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn:xTWM2OD1|MD60O|U6KM7:TR?=NGP2T3FUSU6JRWK=
K5NX3EV3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfITWM2OD1|MD63OlQh|ryPM2S5ZXNCVkeHUh?=
J82M1LxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfuNXREUUN3ME2zNU4xQDl5IN88US=>M2fUe3NCVkeHUh?=
HOP-92M1HseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPaTWM2OD1|MT6xNVEyKM7:TR?=MlrDV2FPT0WU
NCI-H2228M3;6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTNzLkOyPVYh|ryPNFjVcmlUSU6JRWK=
OCI-AML2MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHIS5VKSzVyPUOxMlM3OSEQvF2=M3Ptc3NCVkeHUh?=
NCI-SNU-5MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYn6c3NDUUN3ME2zNU45OTN5IN88US=>NGrkfolUSU6JRWK=
A3-KAWNEPNdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3SweGlEPTB;M{GuPVI1OyEQvF2=Mlm3V2FPT0WU
LCLC-103HMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPpTWM2OD1|Mj6wNVcyKM7:TR?=M{LUOHNCVkeHUh?=
KY821NILpZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\0[IRKSzVyPUOyMlY5QDRizszNMlLGV2FPT0WU
JVM-2M{HFXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HufmlEPTB;M{KuPVA4QSEQvF2=MUHTRW5ITVJ?
Mo-TMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fxR2lEPTB;M{OuNVAxPSEQvF2=MYnTRW5ITVJ?
IA-LMMnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\2OWlEPTB;M{OuNlc2KM7:TR?=M3;oWHNCVkeHUh?=
C8166MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTN|LkOxPVIh|ryPNH\DXnlUSU6JRWK=
TCCSUPM16yUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vINmlEPTB;M{OuOFMxPyEQvF2=M2PmOXNCVkeHUh?=
JEG-3MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFj5NYdKSzVyPUOzMlQ4PjhizszNM3rvSXNCVkeHUh?=
MS-1NIOxdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPxNnlKSzVyPUOzMlU2PTFizszNNHHnO3VUSU6JRWK=
NCI-H1304NFLnOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTN|LkW3NlUh|ryPNIPQN2lUSU6JRWK=
Ramos-2G6-4C10Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTzTWM2OD1|ND6wN|M2KM7:TR?=MVHTRW5ITVJ?
MDA-MB-453MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TKOmlEPTB;M{SuOlM6PSEQvF2=NYXTSXNjW0GQR1XS
KYSE-520MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\YVWlEPTB;M{SuO|E5OSEQvF2=M2jwcHNCVkeHUh?=
SW900NILwRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3ab2wyUUN3ME2zOE45OTF3IN88US=>Mnq3V2FPT0WU
HCC2998MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYO2e|ZpUUN3ME2zOU4yPTJ7IN88US=>NXniWnEyW0GQR1XS
A2058NWfU[5ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDOPZdKSzVyPUO1MlYxPjFizszNM2H4R3NCVkeHUh?=
OVCAR-3NHXMOZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoO4TWM2OD1|Nj6yNFQ2KM7:TR?=M2[2dnNCVkeHUh?=
MOLT-4NF3qPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTN4LkKyPVQh|ryPMnfzV2FPT0WU
CAPAN-1NX3jfllKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4HaR2lEPTB;M{[uOFY6QSEQvF2=MWrTRW5ITVJ?
SCC-9MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn[xTWM2OD1|Nz60NFI4KM7:TR?=MnLCV2FPT0WU
SF268NIT3UXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7Ye4w5UUN3ME2zPE4{PDN|IN88US=>NWfXNIhyW0GQR1XS
HGC-27MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfXT|hKSzVyPUO4MlM4OTFizszNM3fSfXNCVkeHUh?=
DOHH-2MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnv5TWM2OD1|OD63NVU5KM7:TR?=MX\TRW5ITVJ?
KE-37MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nadWlEPTB;M{iuPVgzQCEQvF2=NFvi[WZUSU6JRWK=
MOLT-13MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfhTWM2OD1|OT6yOVAzKM7:TR?=MljmV2FPT0WU
ES1NEHZPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTN7LkO4OUDPxE1?MmX0V2FPT0WU
SK-OV-3Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfzblBKSzVyPUO5Mlk3PDNizszNMlH2V2FPT0WU
SNU-449M1rpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;ZNWZKSzVyPUSwMlA4PjRizszNM2TsW3NCVkeHUh?=
KYSE-510MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDqfFJLUUN3ME20NE4yOjl3IN88US=>MkfPV2FPT0WU
HL-60M{jUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPtV4NKSzVyPUSwMlk4QDNizszNMmfwV2FPT0WU
DJM-1NHS1bm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTRyLkm3PVkh|ryPMX3TRW5ITVJ?
TGBC11TKBNIDiUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjEUGhKSzVyPUSxMlA6OjZizszNNVnBZ3k{W0GQR1XS
U-2-OSMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\4eW1KSzVyPUSyMlI3PDFizszNNIrYSoVUSU6JRWK=
NCI-H2030MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\OeW1HUUN3ME20Nk41OzZ6IN88US=>MnzIV2FPT0WU
LU-135M3zUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37ufGlEPTB;NEKuOVQ1PyEQvF2=M374XXNCVkeHUh?=
ZR-75-30MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDr[Jd6UUN3ME20N{4xPDl|IN88US=>NXy2UndZW0GQR1XS
GT3TKBNXuzVmd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\GTWM2OD12Mz6yOlc6KM7:TR?=M4jab3NCVkeHUh?=
RPMI-2650M{DyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTR|Lke4NVYh|ryPMoXpV2FPT0WU
SASM3;ZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTR|Lkm1N|Qh|ryPMofQV2FPT0WU
MDA-MB-231MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrDe4FMUUN3ME20N{46PjB7IN88US=>M3nI[nNCVkeHUh?=
JVM-3NI[yO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXxVHVsUUN3ME20OE4xPTN|IN88US=>MWnTRW5ITVJ?
COLO-320-HSRM2K0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLOTWM2OD12ND61OlM{KM7:TR?=NFjwdopUSU6JRWK=
SNB75NX3Nb3Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTmTWM2OD12ND62NVA2KM7:TR?=MonNV2FPT0WU
NCI-H441MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLrd|BKSzVyPUS0Mlk{OjhizszNMmfWV2FPT0WU
HCT-116NVPyVZVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPiOpl[UUN3ME20OE46QDZ6IN88US=>NGn5TolUSU6JRWK=
NCI-H226MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{X4U2lEPTB;NEWuOlM3QCEQvF2=MlPEV2FPT0WU
CAL-33MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTR3LkmyNVch|ryPNXzsT4N2W0GQR1XS
NCI-H1437Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4G3U2lEPTB;NE[uN|IyKM7:TR?=M372R3NCVkeHUh?=
HCC1187Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jwUWlEPTB;NE[uOFI2PSEQvF2=Mor1V2FPT0WU
NUGC-3NHnrcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nrVWlEPTB;NE[uOVcxQSEQvF2=NI\qO4tUSU6JRWK=
T98GMn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGT6SplKSzVyPUS3MlU1PyEQvF2=MXfTRW5ITVJ?
OVCAR-8M2TET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLwS3BKSzVyPUS3MlY5OyEQvF2=M{PSWnNCVkeHUh?=
LB2241-RCCNITwNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXqTWM2OD12Nz63Nlch|ryPMULTRW5ITVJ?
NCI-H358M1HMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\MXZg6UUN3ME20PE4yOTV{IN88US=>NVjYUm1KW0GQR1XS
PANC-08-13Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInseFVKSzVyPUS4MlE5PTNizszNMoDHV2FPT0WU
KP-N-YNM1zjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXiSohKSzVyPUS4MlIyODJizszNM4HMVXNCVkeHUh?=
NCI-H1755MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjZ[YJKSzVyPUS4MlI4OjZizszNNITsWINUSU6JRWK=
NCI-N87MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTR6LkK5PVEh|ryPMnzOV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. [1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. [4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. [5]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

In vitro kinase inhibition assays Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl2, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-32P]ATP (5 μM ATP containing 0.4 μCi of [γ-32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.

Cell Assay: [4]

Cell lines KMS11 and KMS18
Concentrations Dissolved in DMSO, final concentrations ~100 nM
Incubation Time 48 hours
Method Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT.

Animal Study: [1]

Animal Models Swiss Webster mice with induced corneal angiogenesis
Formulation Prepared in sterile fashion
Dosages ~2 mg/kg/day
Administration Administered intraperitoneally

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Mohammadi M, et al. EMBO J, 1998, 17(20), 5896-5904.

[2] Skaper SD, et al. J Neurochem, 2000, 75(4), 1520-1527.

view more

Chemical Information

Download PD173074 SDF
Molecular Weight (MW) 523.67
Formula

C28H41N7O3

CAS No. 219580-11-7
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (190.95 mM)
Ethanol 100 mg/mL (190.95 mM)
Water <1 mg/mL
In vivo 5% DMSO+corn oil 15mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 1-tert-butyl-3-(2-(4-(diethylamino)butylamino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea

Frequently Asked Questions

  • Question 1
    What is the half-life of PD173074(S1264) in vivo?

    Answer: According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related FGFR Products

  • CH5183284 (Debio-1347)

    CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.

  • BLU9931

    BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • BGJ398 (NVP-BGJ398)

    BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.

  • AZD4547

    AZD4547 is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.

    Features:Greater selectivity for FGFR1-3 over FGFR4. AZD4547 is active against the tyrosine kinase activity of both the wild-type and mutant forms of FGFR.

  • SSR128129E

    SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

  • LY2874455

    LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Recently Viewed Items

Tags: buy PD173074 | PD173074 supplier | purchase PD173074 | PD173074 cost | PD173074 manufacturer | order PD173074 | PD173074 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us